Medical Developments International (MVP) H2 2025 earnings summary

Executive summary

• Group revenue increased 18% year-over-year to $39.1 million, with strong growth in both Pain Management and Respiratory segments, and margin improvements driven by higher pricing and cost efficiencies.

• Underlying EBIT improved by $11.6 million, reaching breakeven, and reported NPAT swung to a $0.1 million profit from a $41.0 million loss in the prior year.

• Free cash flow improved by $12.9 million, with cash at period end at $17.8 million, supporting future growth investments.

• Delivered volume growth in both pain management (Penthrox) and respiratory segments, meeting all strategic priorities for the year.

• Transitioned Penthrox distribution in France and Switzerland to experienced partners, and secured HPRA approval for pediatric use in Europe, expanding the addressable market.

Financial highlights

• Pain Management revenue rose 23% to $26.2 million, with strong growth in Australia (26%) and Europe (31%).

• Respiratory revenue grew 9% to $12.9 million, with US revenue up 16% and Australian revenue up 11%.

• Free cashflow outflow reduced to $1.1 million, an improvement of $12.9 million year-over-year.

• Underlying EBIT improved from a $11.6 million loss to breakeven.

• Net profit after tax reached $0.1 million, marking the first full-year net profit in several periods.

Outlook and guidance

• FY26 will focus on accelerating volume growth, particularly in pain management by embedding Penthrox as standard of care in hospital EDs and leveraging new pediatric label approvals.

• Increased investment in growth initiatives and commercial/medical activities expected, with a modest cost increase of about $2 million.

• Softer underlying EBIT anticipated in FY26 due to upfront investments and distribution changes, but stronger long-term financial performance expected.

• Launch of pediatric label in Europe and further expansion in the US respiratory market are key priorities.

• Additional pricing benefits of around $1 million expected in FY26 as remaining customers receive price increases.